Intravenous tenecteplase has been shown to be noninferior to alteplase, with a meta-analysis suggesting superiority,1 and although tenecteplase has been used off label, it is replacing alteplase as the preferred thrombolytic agent for the treatment of acute stroke. Aside from the use of thrombolysis for stroke on awakening…
The New England Journal of Medicine: Search Results in Neurology/Neurosurgery
